Document is current
Any future updates will be listed below
-
Authors
Floudas, Charalampos S https://orcid.org/0000-0002-0020-237X
Sarkizova, Siranush https://orcid.org/0000-0003-2530-8610
Ceccarelli, Michele https://orcid.org/0000-0002-4702-6617
Zheng, Wei https://orcid.org/0000-0002-9196-2795
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03313778 at ClinicalTrials.govnct03897881 at ClinicalTrials.govDocuments that mention this clinical trial
1530 T-cell responses to individualized neoantigen therapy (INT) mRNA-4157 (V940) as monotherapy or in combination with pembrolizumab
https://doi.org/10.1136/jitc-2023-sitc2023.1530
Leveraging mRNA technology for antigen based immuno-oncology therapies
https://doi.org/10.1136/jitc-2024-010569
nct01973322 at ClinicalTrials.govDocuments that mention this clinical trial
1530 T-cell responses to individualized neoantigen therapy (INT) mRNA-4157 (V940) as monotherapy or in combination with pembrolizumab
https://doi.org/10.1136/jitc-2023-sitc2023.1530
Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial.
https://doi.org/10.1200/jco.2024.42.17_suppl.lba9512
Leveraging mRNA technology for antigen based immuno-oncology therapies
https://doi.org/10.1136/jitc-2024-010569
Minimal residual disease by circulating tumor DNA as a biomarker of recurrence free survival in resected high-risk melanoma patients treated with mRNA-4157/V940, a personalized cancer vaccine, and pembrolizumab.
https://doi.org/10.1200/jco.2023.41.17_suppl.lba9515
Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.
https://doi.org/10.1200/jco.2023.41.17_suppl.lba9503
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
nct05799612 at ClinicalTrials.govDocuments that mention this clinical trial
Leveraging mRNA technology for antigen based immuno-oncology therapies
https://doi.org/10.1136/jitc-2024-010569
nct00514189 at ClinicalTrials.govDocuments that mention this clinical trial
Leveraging mRNA technology for antigen based immuno-oncology therapies
https://doi.org/10.1136/jitc-2024-010569
Documents that mention this clinical trial
Leveraging mRNA technology for antigen based immuno-oncology therapies
https://doi.org/10.1136/jitc-2024-010569
- License Information
